Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 7/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898690 | 0.94 | CNR2 (0.40) | PIK3CACNR2CNR1CD274HPGD | |
| SCHEMBL4906678 | 0.90 | KMT2A (0.42) | PIK3CACNR2CNR1CD274HPGD | |
| SCHEMBL4576555 | 0.89 | DRD1 (0.43) | CNR2CNR1HPGDHTR2AKMT2A | |
| SCHEMBL16021049 | 0.87 | GRIN2B (0.41) | TSHRKMT2A | |
| SCHEMBL4896142 | 0.86 | CNR1 (0.37) | PIK3CACNR2CNR1KMT2A | |
| SCHEMBL4904302 | 0.86 | HIF1A (0.38) | TSHRKMT2A | |
| SCHEMBL4901109 | 0.85 | HIF1A (0.38) | HPGDTSHRKMT2A | |
| SCHEMBL4907166 | 0.85 | HIF1A (0.38) | TSHRKMT2A | |
| SCHEMBL16021048 | 0.85 | MEN1 (0.41) | HPGDTSHRKMT2A | |
| SCHEMBL6064605 | 0.84 | MEN1 (0.40) | HPGDTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | SHIONOGI & CO. LTD (JP) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | API5, ING2, SAMHD1 | PIK3CA 548/4885CNR2 4815/4885CNR1 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.